Clear Street Starts Madrigal Pharmaceuticals (MDGL) at Buy, 'bullish view on Rezdiffra’s launch and its revenue-generating potential'
Tweet Send to a Friend
(Updated - January 30, 2025 4:56 PM EST)
Clear Street analyst Kaveri Pohlman initiates coverage on Madrigal Pharmaceuticals (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Clear Street analyst Kaveri Pohlman initiates coverage on Madrigal Pharmaceuticals (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
